Brief: Inflarx’S Marketing Authorization Application (Maa) For Vilobelimab
30/08/2023 13:04
Aug 30 (Reuters) - InflaRx NV IF0G.F :
* INFLARX’S MARKETING AUTHORIZATION APPLICATION (MAA) FOR
VILOBELIMAB FOR TREATMENT OF CRITICALLY ILL COVID-19 PATIENTS
UNDER REVIEW BY EUROPEAN MEDICINES AGENCY (EMA)
* INFLARX NV: MAA FOR VILOBELIMAB WAS SUBMITTED IN JULY
* INFLARX NV: MAA HAS BEEN VALIDATED BY EMA AND IS NOW UNDER
REVIEW
Source text for Eikon: ID:nGNX6K1kTj
Further company coverage: IF0G.F
Recent news on Inflarx NV
See all newsBrief: Inflarx NV Files For Offerng Of Ordinary Shares, Size Not Disclosed - SEC Filing
Brief: InflaRx Reports Full Year 2025 Results And Highlights Key Achievements And Expected Milestones
Brief: Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting
Brief: Inflarx NV Executing 30% Workforce Reduction
Brief: Inflarx Provides Update On Phase 3 Data Analyses For Vilobelimab In Pyoderma Gangrenosum